- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Malignant pleural mesothelioma
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1721KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 739KB)
Nivolumab and ipilimumab – March 2021
Nivolumab and Ipilimumab; Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL; Yervoy®
Last updated
2 July 2021